Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
IMSA101 / ImmuneSensor Therap
SPARK, NCT06601296: Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer	Recruiting	2	15	US	IMSA101	University of Texas Southwestern Medical Center	Metastatic Renal Cell Carcinoma ( mRCC), OligoProgressive Metastatic Disease	10/27	10/28
NCT05846646: Study of PULSAR-ICI +/- IMSA101 in Patients with Oligometastatic NSCLC and RCC	Terminated	2	6	US	IMSA101, Immune checkpoint inhibitor, pembrolizumab, nivolumab, PULSAR	ImmuneSensor Therapeutics Inc.	Oligometastatic Disease	09/24	09/24
NCT05846659: Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies	Terminated	2	16	US	IMSA101, Immune checkpoint inhibitor, pembrolizumab, nivolumab, PULSAR	ImmuneSensor Therapeutics Inc.	Oligoprogressive	11/24	11/24
NCT04020185: Safety and Efficacy Study of IMSA101 in Refractory Malignancies	Completed	1/2	40	US	IMSA101, Immune checkpoint inhibitor (ICI), Immuno-oncology (IO) therapy	ImmuneSensor Therapeutics Inc.	Solid Tumor, Adult	09/23	09/23
NCT06026254: A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial	Active, not recruiting	1	2	US	IMSA101, Immune Checkpoint Inhibitor, ICI	ImmuneSensor Therapeutics Inc.	Solid Tumor, Adult	09/25	09/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
IMSA101 / ImmuneSensor Therap
SPARK, NCT06601296: Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer	Recruiting	2	15	US	IMSA101	University of Texas Southwestern Medical Center	Metastatic Renal Cell Carcinoma ( mRCC), OligoProgressive Metastatic Disease	10/27	10/28
NCT05846646: Study of PULSAR-ICI +/- IMSA101 in Patients with Oligometastatic NSCLC and RCC	Terminated	2	6	US	IMSA101, Immune checkpoint inhibitor, pembrolizumab, nivolumab, PULSAR	ImmuneSensor Therapeutics Inc.	Oligometastatic Disease	09/24	09/24
NCT05846659: Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies	Terminated	2	16	US	IMSA101, Immune checkpoint inhibitor, pembrolizumab, nivolumab, PULSAR	ImmuneSensor Therapeutics Inc.	Oligoprogressive	11/24	11/24
NCT04020185: Safety and Efficacy Study of IMSA101 in Refractory Malignancies	Completed	1/2	40	US	IMSA101, Immune checkpoint inhibitor (ICI), Immuno-oncology (IO) therapy	ImmuneSensor Therapeutics Inc.	Solid Tumor, Adult	09/23	09/23
NCT06026254: A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial	Active, not recruiting	1	2	US	IMSA101, Immune Checkpoint Inhibitor, ICI	ImmuneSensor Therapeutics Inc.	Solid Tumor, Adult	09/25	09/25